ELUCID
Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.
ELUCID
Industry:
Analytics Biotechnology Medical Device
Founded:
2013-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.elucid.com
Total Employee:
51+
Status:
Active
Contact:
617-329-9487
Email Addresses:
[email protected]
Total Funding:
49.73 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail GoDaddy DNS Google Google Cloud COVID-19 DMARC Shutterstock
Similar Organizations
Enlitic
Enlitic builds AI deep learning products to streamline radiologists' workflows and improve healthcare diagnosis.
Gelesis
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Employees Featured
Founder
Investors List
IAG Capital Partners
IAG Capital Partners investment in Series B - Elucid
Aphelion Capital
Aphelion Capital investment in Series B - Elucid
Bold Brain Ventures
Bold Brain Ventures investment in Series B - Elucid
Biovision Ventures
Biovision Ventures investment in Series B - Elucid
BlueStone Venture Partners
BlueStone Venture Partners investment in Series B - Elucid
MedTex Ventures
MedTex Ventures investment in Series B - Elucid
MedTex Ventures
MedTex Ventures investment in Series A - Elucid
Wolverine Venture Fund
Wolverine Venture Fund investment in Series A - Elucid
IAG Capital Partners
IAG Capital Partners investment in Series A - Elucid
Global Health Impact Fund
Global Health Impact Fund investment in Series A - Elucid
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-26 | Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer |
Official Site Inspections
http://www.elucid.com Semrush global rank: 4.86 M Semrush visits lastest month: 1.82 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Elucid"
Home - Elucid
Ninety percent of producers and workers face barriers to affordable healthcare, often forcing them to pay medical expenses out-of-pocket. This financial pressure pushes many families further …See details»
Elucid | See Beyond the Lumen
Elucid Clinical Research Use Elucid’s CTA analysis capabilities for potential research on events tracking, pharma research and more.See details»
Elucid - Crunchbase Company Profile & Funding
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.See details»
Elucid Org Chart + Executive Team - The Official Board
The org chart of Elucid contains its 18 main executives like Kelly Huang, Blake Richards and Andrew Miller.See details»
Elucid Names Kelly Huang as CEO - Business Wire
Jul 22, 2024 Elucid names Kelly Huang, PhD, as president and CEO as part of preparations for commercialization of its flagship plaque analysis software, PlaqueIQ.See details»
Elucid - MGMT Boston
The market Elucid is going after is today in the billions but growing significantly. Elucid is in an exciting transitional phase from being an engineering led research organization to a more well rounded scaled commercial organization.See details»
News - Elucid
Nov 4, 2024 Elucid, Inc., a medical technology company providing physicians AI-powered imaging analysis software to characterize cardiovascular disease, has announced that the company’s technology will be featured on the program …See details»
Elucid Names Kelly Huang as CEO
Mr. Huang’s appointment as CEO follows Elucid’s $80 million Series C fundraise in Q4 2023, led by Elevage Medical Technologies, which is intended to help further commercialization and …See details»
Elucid Raises $80 Million in Series C Round Led by Elevage Medical ...
Nov 9, 2023 Investment will drive commercialization and expansion of AI-powered non-invasive diagnostic tools to help evaluate cardiovascular risk BOSTON, Nov. 9, 2023 – Elucid, a …See details»
Elucid Names Richard E. Kuntz, MD, MSc and …
3 days ago About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root …See details»
Andrew Miller Joins Elucid as Chief Technology Officer
Mar 28, 2023 He joins Elucid from Engooden Health, where he served as CTO and chief information security officer, responsible for delivery of technology solutions and infrastructure …See details»
Team - Elucid
Julius and Samuel, both medical doctors and social entrepreneurs with over a decade of experience improving healthcare in some of the world’s most challenging regions, founded …See details»
Elucid - Partnerships | Unorthodox Ventures
ELUCID'S STORY Accurate clinical insights based on biology Patients with known or suspected cardiovascular disease are at risk for deadly events like heart attacks and strokes. A peek …See details»
Elucid Names Richard E. Kuntz and Shamiram Feinglass Board …
3 days ago BOSTON & SCCT ANNUAL MEETING, MONTREAL-- (BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view …See details»
Elucid adds senior members as it prepares for PlaqueIQ launch
Mar 4, 2025 Elucid has added several senior members to its clinical and commercial teams as the company prepares for the commercial launch of PlaqueIQ.See details»
Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, …
3 days ago These appointments will help guide Elucid as it accelerates its clinical research strategy, commercializes its flagship PlaqueIQ TM coronary plaque assessment technology, …See details»
Elucid Raises $27 Million Series B Funding Round to …
BOSTON – June 22, 2022 – Elucid, a company developing a novel, non-invasive medical software to comprehensively characterize cardiovascular disease, announced the closing of a …See details»
Solution - Elucid
This also increases productivity and consumer trust. Elucid’s solution for fair and sustainable value chains revolves around three key services: Health Programs, Financial Services, and …See details»
Elucid - Wikipedia
Elucid (often stylized as E L U C I D), is an American rapper and record producer from New York City. He has been a member of Armand Hammer, [1] Cult Favorite, [2] Lessondary, [3] …See details»
Faqs - Elucid
Elucid adopts a partner-agnostic approach, collaborating with a diverse range of health facilities that span both public and private sectors, including faith-based organizations. Our primary …See details»